CClinicalTrials.gg
RecruitingNCT06550531HPV-AMPUpdated Aug 13, 2024

Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)

An observational study in Human Papilloma Virus and Infertility, Female, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to female participants aged 25 Years to 38 Years. Per ClinicalTrials.gov, last updated 2024-08-13.

Sponsored by University Hospital, Brest · Observational

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2022; still recruiting 4 years 8 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
618
Ages
25 Years to 38 Years
Sex
Female
01

Study summary

The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.

Read the detailed description

This is a single-center prospective study in the assisted reproduction center of Brest University Hospital. All new patients coming to consult will be offered participation in the study. The HPV test will be updated if it is older than 12 months. We will analyze stimulation results and pregnancy outcomes according to HPV status. Inclusions will take place over 3 years

02

Conditions studied

  • Human Papilloma Virus
  • Infertility, Female
03

In context

Papilloma

234 studies on the registry are indexed under Papilloma; 28 are open to participants now.

This study's planned enrollment of 618 is above the median of 188 across 64 observational studies indexed under Papilloma.

Browse Papilloma studies →

Lead sponsor

University Hospital, Brest is the lead sponsor of 594 studies on the registry; 135 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
25 Years to 38 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The population study is a population of infertile women who are consulting in our center of Reproduction Médicine in CHU Brest.

Inclusion criteria

  • all etiology of infertility AMH > ou = à 1.1 ng/ml First ou second protocol of IVF between 25 years and 37 years and 11 months

Exclusion criteria

Exclusion Criteria:

Age \< 25 y Age > ou = 38 y AMH \< 1.1 ng/ml patient under juridic protection rejection of participation

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
618 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. clinical pregnancy rate after fresh eSET by HPV status

    A clinical pregancy is the visualisation of a gestational sac inside the uterus after 6 weeks of gestation

    Time frame: 1 year

Secondary outcomes

  1. IVF issues

    oocytes number, embryos number, fecondation rate, implantation rate

    Time frame: 1 year

  2. Positive HPV rate

    number of women who have a positive HPV test before IVF procedure

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected data that underlie results in a publication

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06550531
Lead sponsor
University Hospital, Brest
Responsible party
Sponsor
First posted
Aug 13, 2024
Start date
Feb 4, 2022
Primary completion
Feb 4, 2026 (estimated)
Completion
Feb 4, 2026 (estimated)
Last update
Aug 13, 2024

Study contacts

Sarah BOUEE
Contact
sarah.bouee@chu-brest.fr
02 98 22 39 70
Anne-Solenn JACAMON
Contact
anne-solenn.jacamon@chu-brest.fr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion